Evotec 

$7.1
256
+$0+0% Tuesday 20:00

统计数据

当日最高
6.96
当日最低
6.96
52周最高
24.61
52周最低
6.57
成交量
100
平均成交量
58
市值
1.31B
市盈率
-
股息收益率
-
股息
-

即将到来

收益

6Nov预期
Q3 2021
Q1 2022
Q2 2022
Q3 2022
Q1 2024
Q2 2024
下一个
-0.58
-0.11
0.35
0.82
预期每股收益
-0.04797136432
实际每股收益
N/A

人们还关注

此列表基于关注EVOTF的Stock Events用户的观察列表。这不是投资建议。

竞争者

这个列表是基于最近市场事件的分析。这不是投资建议。

关于

Biotechnology
Health Technology
Pharmaceuticals: Major
Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as diabetes and complications of diabetes, fibrosis, infectious diseases, CNS diseases, oncology, pain and inflammation, immunology, rare diseases, respiratory diseases, and women's health. It has collaboration agreements with Bayer AG; Lilly; Chinook Therapeutics; Novo Nordisk A/S; Galapagos; Pfizer Inc.; CONBA Pharmaceutical Co., Ltd.; Bristol Myers Squibb Company; Zhejiang JingXin Pharmaceutical Co., Ltd; Kazia Therapeutics; Apeiron Biologics; and Takeda Pharmaceuticals. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.
Show more...
首席执行官
Werner Lanthaler
员工
5022
国家
DE
ISIN
DE0005664809

上市公司